Erratum: The prebiotic concept and human health: a changing landscape with riboflavin as a novel prebiotic candidate? (European Journal of Clinical Nutrition, (2016), 70, 12, (1348-1353), 10.1038/ejcn.2016.119);The prebiotic concept and human health: A changing landscape with riboflavin as a novel prebiotic candidate

European Journal of Clinical Nutrition

Volumn 70, Issue 12, 2016, Pages 1348-1353

  Steinert, R E ^a   Sadaghian Sadabad, M ^b   Harmsen, H J M ^b   Weber, P ^a  

^a DSM NUTRITIONAL PRODUCTS LTD   (Switzerland)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

POLYPHENOL; PREBIOTIC AGENT; RIBOFLAVIN; SHORT CHAIN FATTY ACID; VITAMIN B COMPLEX;

ANTIMICROBIAL ACTIVITY; BACTERIAL COUNT; BACTERIAL GROWTH; BACTEROIDES; BIFIDOBACTERIUM; CLOSTRIDIUM; ENTEROCOCCUS; ESCHERICHIA COLI; FAECALIBACTERIUM; FAECALIBACTERIUM PRAUSNITZII; FOOD COMPOSITION; HUMAN; HYDROLYSIS; INTESTINE ABSORPTION; INTESTINE FLORA; LACTOBACILLUS; LIPID COMPOSITION; NONHUMAN; REVIEW; SALMONELLA; STOMACH PH; FUNCTIONAL FOOD; MICROBIOLOGY;

FUNCTIONAL FOOD; GASTROINTESTINAL MICROBIOME; HUMANS; PREBIOTICS; RIBOFLAVIN; VITAMIN B COMPLEX;

EID: 84978115955     PISSN: 09543007     EISSN: 14765640     Source Type: Journal    
DOI: 10.1038/ejcn.2016.141     Document Type: Erratum

References (97)

1. Owyang C, Wu GD. The gut microbiome in health and disease. Gastroenterology 2014; 146: 1433-1436.
2. Marchesi JR, Adams DH, Fava F, Hermes GD, Hirschfield GM, Hold G et al. The gut microbiota and host health: A new clinical frontier. Gut 2015; 65: 330-339.
3. Frank St DN, Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecularphylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA 2007; 104: 13780-13785.
4. de Goffau MC, Luopajarvi K, Knip M, Ilonen J, Ruohtula T, Harkonen T et al. Fecal microbiota composition differs between children with beta-cell autoimmunity and those without. Diabetes 2013; 62: 1238-1244.
5. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature 2006; 444: 1022-1023.
6. Cryan JF, Dinan TG. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci 2012; 13: 701-712.
7. Grenham S, Clarke G, Cryan JF, Dinan TG. Brain-gut-microbe communication in health and disease. Front Physiol 2011; 2: 94.
8. Metchnikoff E. The prolongation of life: optimistic studies. In: Chalmers Mitchell P (ed). GP Putnam's Sons: New York, London, 1908.
9. van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368: 407-415.
10. Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr 1995; 125: 1401-1412.
11. David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 2014; 505: 559-563.
12. Cani PD, Possemiers S, Van de Wiele T, Guiot Y, Everard A, Rottier O et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 2009; 58: 1091-1103.
13. Cani PD, Lecourt E, Dewulf EM, Sohet FM, Pachikian BD, Naslain D et al. Gut microbiota fermentation of prebiotics increases satietogenic and incretin gut peptide production with consequences for appetite sensation and glucose response after a meal. Am J Clin Nutr 2009; 90: 1236-1243.
14. Kellow NJ, Coughlan MT, Reid CM. Metabolic benefits of dietary prebiotics in human subjects: A systematic review of randomised controlled trials. Br J Nutr 2014; 111: 1147-1161.
15. Yazawa K, Imai K, Tamura Z. Oligosaccharides and polysaccharides specifically utilizable by bifidobacteria. Chem Pharm Bull (Tokyo) 1978; 26: 3306-3311.
16. Mitsuoka T, Hidaka H, Eida T. Effect of fructo-oligosaccharides on intestinal microflora. Nahrung 1987; 31: 427-436.
17. Gibson GR, Probert HM, Loo JV, Rastall RA, Roberfroid MB. Dietary modulation of the human colonic microbiota: updating the concept of prebiotics. Nutr Res Rev 2004; 17: 259-275.
18. Roberfroid M. Prebiotics: the concept revisited. J Nutr 2007; 137(Suppl 2): 830S-837S.
19. Gibson GR, Scott KP, Rastall RA, Tuohy KM, Hotchkiss A, Dubert-Ferrandon A et al. Dietary prebiotics: current status and new definition. Food Sci Technol Bull (Funct Foods) 2010; 1-19.
20. Bindels LB, Delzenne NM, Cani PD, Walter J. Towards a more comprehensive concept for prebiotics. Nat Rev Gastroenterol Hepatol 2015; 12: 303-310.
21. Pineiro M, Asp NG, Reid G, Macfarlane S, Morelli L, Brunser O et al. FAO Technical meeting on prebiotics. J Clin Gastroenterol 2008; 42: S156-S159.
22. Hutkins RW, Krumbeck JA, Bindels LB, Cani PD, Fahey Jr G, Goh YJ et al. Prebiotics: why definitions matter. Curr Opin Biotechnol 2016; 37: 1-7.
23. Reid G, Sanders ME, Gaskins HR, Gibson GR, Mercenier A, Rastall R et al. New scientific paradigms for probiotics and prebiotics. J Clin Gastroenterol 2003; 37: 105-118.
24. De Filippo C, Cavalieri D, Di Paola M, Ramazzotti M, Poullet JB, Massart S et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci USA 2010; 107: 14691-14696.
25. Chassard C, Lacroix C. Carbohydrates and the human gut microbiota. Curr Opin Clin Nutr Metab Care 2013; 16: 453-460.
26. Marcobal A, Sonnenburg JL. Human milk oligosaccharide consumption by intestinal microbiota. Clin Microbiol Infect 2012; 18: 12-15.
27. Nyangale EP, Mottram DS, Gibson GR. Gut microbial activity, implications for health and disease: the potential role of metabolite analysis. J Proteome Res 2012; 11: 5573-5585.
28. Riviere A, Gagnon M, Weckx S, Roy D, De Vuyst L. Mutual cross-feeding interactions between Bifidobacterium longum NCC2705 and Eubacterium rectale ATCC 33656 explain the bifidogenic and butyrogenic effects of arabinoxylan-oligosaccharides. Appl Environ Microbiol 2015; 81: 7767-7781.
29. Salyers AA. Energy sources of major intestinal fermentative anaerobes. Am J Clin Nutr 1979; 32: 158-163.
30. Hickson M, D'Souza AL, Muthu N, Rogers TR, Want S, Rajkumar C et al. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ 2007; 335: 80.
31. Bouhnik Y, Flourie B, D'Agay-Abensour L, Pochart P, Gramet G, Durand M et al. Administration of transgalacto-oligosaccharides increases fecal bifidobacteria and modifies colonic fermentation metabolism in healthy humans. J Nutr 1997; 127: 444-448.
32. Jaskari J, Kontula P, Siitonen A, Jousimies-Somer H, Mattila-Sandholm T, Poutanen K. Oat beta-glucan and xylan hydrolysates as selective substrates for Bifidobacterium and Lactobacillus strains. Appl Microbiol Biotechnol 1998; 49: 175-181.
33. Kleessen B, Sykura B, Zunft HJ, Blaut M. Effects of inulin and lactose on fecal microflora, microbial activity, and bowel habit in elderly constipated persons. Am J Clin Nutr 1997; 65: 1397-1402
34. Rastall RA, Gibson GR. Recent developments in prebiotics to selectively impact beneficial microbes and promote intestinal health. Curr Opin Biotechnol 2015; 32: 42-46.
35. Borriello SP, Hammes WP, Holzapfel W, Marteau P, Schrezenmeir J, Vaara M et al. Safety of probiotics that contain lactobacilli or bifidobacteria. Clin Infect Dis 2003; 36: 775-780.
36. Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M et al. Diversity of the human intestinal microbial flora. Science 2005; 308: 1635-1638.
37. Verbeke KA, Boobis AR, Chiodini A, Edwards CA, Franck A, Kleerebezem M et al. Towards microbial fermentation metabolites as markers for health benefits of prebiotics. Nutr Res Rev 2015; 28: 42-66.
38. Lewis S, Burmeister S, Brazier J. Effect of the prebiotic oligofructose on relapse of Clostridium difficile-associated diarrhea: A randomized, controlled study. Clin Gastroenterol Hepatol 2005; 3: 442-448.
39. Whelan K. Probiotics and prebiotics in the management of irritable bowel syndrome: A review of recent clinical trials and systematic reviews. Curr Opin Clin Nutr Metab Care 2011; 14: 581-587.
40. Leenen CH, Dieleman LA. Inulin and oligofructose in chronic inflammatory bowel disease. J Nutr 2007; 137(11 Suppl): 2572S-2575S.
41. Drakoularakou A, Tzortzis G, Rastall RA, Gibson GR. A double-blind, placebocontrolled, randomized human study assessing the capacity of a novel galactooligosaccharide mixture in reducing travellers' diarrhoea. Eur J Clin Nutr 2010; 64: 146-152.
42. Osborn DA, Sinn JK. Prebiotics in infants for prevention of allergy. Cochrane Database Syst Rev 2013; 3: CD006474.
43. Verhoef SP, Meyer D, Westerterp KR. Effects of oligofructose on appetite profile, glucagon-like peptide 1 and peptide YY3-36 concentrations and energy intake. Br J Nutr 2011; 106: 1757-1762.
44. Parnell JA, Reimer RA. Weight loss during oligofructose supplementation is associated with decreased ghrelin and increased peptide YY in overweight and obese adults. Am J Clin Nutr 2009; 89: 1751-1759.
45. Frost G, Sleeth ML, Sahuri-Arisoylu M, Lizarbe B, Cerdan S, Brody L et al. The shortchain fatty acid acetate reduces appetite via a central homeostatic mechanism. Nat Commun 2014; 5: 3611.
46. Canfora EE, Jocken JW, Blaak EE. Short-chain fatty acids in control of body weight and insulin sensitivity. Nat Rev Endocrinol 2015; 11: 577-591.
47. De Vadder F, Kovatcheva-Datchary P, Goncalves D, Vinera J, Zitoun C, Duchampt A et al. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell 2014; 156: 84-96.
48. Roberfroid M, Gibson GR, Hoyles L, McCartney AL, Rastall R, Rowland I et al. Prebiotic effects: metabolic and health benefits. Br J Nutr 2010; 104: S1-S63.
49. Gibson GR, Fuller R. Aspects of in vitro and in vivo research approaches directed toward identifying probiotics and prebiotics for human use. J Nutr 2000; 130: 391S-395S.
50. Bird AR, Conlon MA, Christophersen CT, Topping DL. Resistant starch, large bowel fermentation and a broader perspective of prebiotics and probiotics. Benef Microbes 2010; 1: 423-431.
51. Vrieze A, Van Nood E, Holleman F, Salojarvi J, Kootte RS, Bartelsman JF et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012; 143: 913-916 e917.
52. Slavin J. Fiber and prebiotics: mechanisms and health benefits. Nutrients 2013; 5: 1417-1435.
53. Hamaker BR, Tuncil YE. A perspective on the complexity of dietary fiber structures and their potential effect on the gut microbiota. J Mol Biol 2014; 426: 3838-3850.
54. Birt DF, Boylston T, Hendrich S, Jane JL, Hollis J, Li L et al. Resistant starch: promise for improving human health. Adv Nutr 2013; 4: 587-601.
55. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermudez-Humaran LG, Gratadoux JJ et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 2008; 105: 16731-16736.
56. Quevrain E, Maubert MA, Michon C, Chain F, Marquant R, Tailhades J et al. Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn's disease. Gut 2016; 65: 415-425.
57. Everard A, Lazarevic V, Derrien M, Girard M, Muccioli GG, Neyrinck AM et al. Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice. Diabetes 2011; 60: 2775-2786.
58. Atarashi K, Tanoue T, Oshima K, Suda W, Nagano Y, Nishikawa H et al. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature 2013; 500: 232-236.
59. Dewulf EM, Cani PD, Claus SP, Fuentes S, Puylaert PG, Neyrinck AM et al. Insight into the prebiotic concept: lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women. Gut 2013; 62: 1112-1121.
60. Serino M, Luche E, Gres S, Baylac A, Berge M, Cenac C et al. Metabolic adaptation to a high-fat diet is associated with a change in the gut microbiota. Gut 2012; 61: 543-553.
61. Anhe FF, Roy D, Pilon G, Dudonne S, Matamoros S, Varin TV et al. A polyphenolrich cranberry extract protects from diet-induced obesity, insulin resistance and intestinal inflammation in association with increased Akkermansia spp. population in the gut microbiota of mice. Gut 2015; 64: 872-883.
62. Neyrinck AM, Van Hee VF, Bindels LB, De Backer F, Cani PD, Delzenne NM. Polyphenol-rich extract of pomegranate peel alleviates tissue inflammation and hypercholesterolaemia in high-fat diet-induced obese mice: potential implication of the gut microbiota. Br J Nutr 2013; 109: 802-809.
63. Salminen S, van Loveren H. Probiotics and prebiotics: health claim substantiation. Microb Ecol Health Dis 2012; 18: 23.
64. EFSA Panel on Dietetic Products, Nutrition and Allergies. Scientific Opinion on the substantiation of a health claim related to 'native chicory inulin' and maintenance of normal defecation by increasing stool frequency pursuant to Article 13. 5 of Regulation (EC) No 1924/2006. EFSA J 2015; 13: 3951.
65. EFSA Panel on Dietetic Products, Nutrition and Allergies. Guidance on the scientific requirements for health claims related to the immune system, the gastrointestinal tract and defence against pathogenic microorganisms. EFSA J 2016; 14: 23.
66. Duenas M, Munoz-Gonzalez I, Cueva C, Jimenez-Giron A, Sanchez-Patan F, Santos-Buelga C et al. A survey of modulation of gut microbiota by dietary polyphenols. Biomed Res Int 2015; 2015: 850902.
67. Queipo-Ortuno MI, Boto-Ordonez M, Murri M, Gomez-Zumaquero JM, Clemente-Postigo M, Estruch R et al. Influence of red wine polyphenols and ethanol on the gut microbiota ecology and biochemical biomarkers. Am J Clin Nutr 2012; 95: 1323-1334.
68. Chaplin A, Parra P, Laraichi S, Serra F, Palou A. Calcium supplementation modulates gut microbiota in a prebiotic manner in dietary obese mice. Mol Nutr Food Res 2016; 60: 468-480.
69. Khan MT, Browne WR, van Dijl JM, Harmsen HJ. How can Faecalibacterium prausnitzii employ riboflavin for extracellular electron transfer? Antioxid Redox Signal 2012; 17: 1433-1440.
70. Khan MT, Duncan SH, Stams AJ, van Dijl JM, Flint HJ, Harmsen HJ. The gut anaerobe Faecalibacterium prausnitzii uses an extracellular electron shuttle to grow at oxic-anoxic interphases. ISME J 2012; 6: 1578-1585.
71. Clifford MN. Diet-derived phenols in plasma and tissues and their implications for health. Planta Med 2004; 70: 1103-1114.
72. Rigottier-Gois L. Dysbiosis in inflammatory bowel diseases: the oxygen hypothesis. ISME J 2013; 7: 1256-1261.
73. Carmel-Harel O, Storz G. Roles of the glutathione-and thioredoxin-dependent reduction systems in the Escherichia coli and Saccharomyces cerevisiae responses to oxidative stress. Annu Rev Microbiol 2000; 54: 439-461.
74. Jones SA, Gibson T, Maltby RC, Chowdhury FZ, Stewart V, Cohen PS et al. Anaerobic respiration of Escherichia coli in the mouse intestine. Infect Immun 2011; 79: 4218-4226.
75. Winter SE, Winter MG, Xavier MN, Thiennimitr P, Poon V, Keestra AM et al. Host-derived nitrate boosts growth of E. coli in the inflamed gut. Science 2013; 339: 708-711.
76. Winter SE, Thiennimitr P, Winter MG, Butler BP, Huseby DL, Crawford RW et al. Gut inflammation provides a respiratory electron acceptor for Salmonella. Nature 2010; 467: 426-429.
77. Neish AS, Jones RM. Redox signaling mediates symbiosis between the gut microbiota and the intestine. Gut Microbes 2014; 5: 250-253.
78. Schroeder BO, Wu Z, Nuding S, Groscurth S, Marcinowski M, Beisner J et al. Reduction of disulphide bonds unmasks potent antimicrobial activity of human beta-defensin 1. Nature 2011; 469: 419-423.
79. Espey MG. Role of oxygen gradients in shaping redox relationships between the human intestine and its microbiota. Free Radic Biol Med 2013; 55: 130-140.
80. Albenberg L, Esipova TV, Judge CP, Bittinger K, Chen J, Laughlin A et al. Correlation between intraluminal oxygen gradient and radial partitioning of intestinal microbiota. Gastroenterology 2014; 147: 1055-1063 e1058.
81. Van den Abbeele P, Van de Wiele T, Verstraete W, Possemiers S. The host selects mucosal and luminal associations of coevolved gut microorganisms: A novel concept. FEMS Microbiol Rev 2011; 35: 681-704.
82. Jusko WJ, Levy G. Absorption, metabolism, and excretion of riboflavin-5'-phosphate in man. J Pharm Sci 1967; 56: 58-62.
83. McCormick DB. Two interconnected B vitamins: riboflavin and pyridoxine. Physiol Rev 1989; 69: 1170-1198.
84. Zempleni J, Galloway JR, McCormick DB. Pharmacokinetics of orally and intravenously administered riboflavin in healthy humans. Am J Clin Nutr 1996; 63: 54-66.
85. Heinken A, Khan MT, Paglia G, Rodionov DA, Harmsen HJ, Thiele I. Functional metabolic map of Faecalibacterium prausnitzii, a beneficial human gut microbe. J Bacteriol 2014; 196: 3289-3302.
86. Condo M, Posar A, Arbizzani A, Parmeggiani A. Riboflavin prophylaxis in pediatric and adolescent migraine. J Headache Pain 2009; 10: 361-365.
87. Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology 1998; 50: 466-470.
88. Boehnke C, Reuter U, Flach U, Schuh-Hofer S, Einhaupl KM, Arnold G. High-dose riboflavin treatment is efficacious in migraine prophylaxis: An open study in a tertiary care centre. Eur J Neurol 2004; 11: 475-477.
89. Sadaghian Sadabad M. Interaction between the gut and its microbiota in inflammatory bowel disease. PhD thesis, University of Groningen, Groningen, The Netherlands, 2015, ISBN 9789462990340.
90. Lopez-Siles M, Khan TM, Duncan SH, Harmsen HJ, Garcia-Gil LJ, Flint HJ. Cultured representatives of two major phylogroups of human colonic Faecalibacterium prausnitzii can utilize pectin, uronic acids, and host-derived substrates for growth. Appl Environ Microbiol 2012; 78: 420-428.
91. Ploger S, Stumpff F, Penner GB, Schulzke JD, Gabel G, Martens H et al. Microbial butyrate and its role for barrier function in the gastrointestinal tract. Ann NY Acad Sci 2012; 1258: 52-59.
92. Rossi O, Khan MT, Schwarzer M, Hudcovic T, Srutkova D, Duncan SH et al. Faecalibacterium prausnitzii strain HTF-F and its extracellular polymeric matrix attenuate clinical parameters in DSS-induced colitis. PLoS One 2015; 10: e0123013.
93. Willing B, Halfvarson J, Dicksved J, Rosenquist M, Jarnerot G, Engstrand L et al. Twin studies reveal specific imbalances in the mucosa-associated microbiota of patients with ileal Crohn's disease. Inflamm Bowel Dis 2009; 15: 653-660.
94. Winter SE, Baumler AJ. A breathtaking feat: to compete with the gut microbiota, Salmonella drives its host to provide a respiratory electron acceptor. Gut Microbes 2011; 2: 58-60.
95. Gill N, Ferreira RB, Antunes LC, Willing BP, Sekirov I, Al-Zahrani F et al. Neutrophil elastase alters the murine gut microbiota resulting in enhanced Salmonella colonization. PLoS One 2012; 7: e49646.
96. Vong L, Pinnell LJ, Maattanen P, Yeung CW, Lurz E, Sherman PM. Selective enrichment of commensal gut bacteria protects against Citrobacter rodentiuminduced colitis. Am J Physiol Gastrointest Liver Physiol 2015; 309: G181-G192.
97. Benus RF, van der Werf TS, Welling GW, Judd PA, Taylor MA, Harmsen HJ et al. Association between Faecalibacterium prausnitzii and dietary fibre in colonic fermentation in healthy human subjects. Br J Nutr 2010; 104: 693-700.